We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.08% | 25.62 | 25.83 | 25.585 | 25.67 | 37,734,167 | 21:20:00 |
From Apr 2019 to Apr 2024
By Pietro Lombardi
European Union antitrust authorities conditionally approved late Wednesday the acquisition by GlaxoSmithKline PLC (GSK.LN) of Pfizer Inc.'s (PFE) consumer health business.
The approval is contingent on the sale of Pfizer's ThermaCare business, which makes products that cover topical pain management.
The deal in its original form would have reduced competition for topical pain management products, and could have caused an increase in prices in several European countries, including Germany, Italy and the Netherlands.
"These assets will have to be divested as a package to one suitable purchaser to be approved by the Commission," the European Commission said.
The sale of the business removes almost completely the overlap between the companies' activities in the field, it said.
Write to Pietro Lombardi at pietro.lombardi@dowjones.com
(END) Dow Jones Newswires
July 11, 2019 04:47 ET (08:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
